New hope for ventilator patients: inhaled drug may prevent deadly pneumonia
NCT ID NCT06834971
First seen May 19, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This study tests whether a 3-day course of inhaled colistin can prevent ventilator-associated pneumonia (VAP) in adults on breathing machines who are at high risk for drug-resistant infections. About 508 participants will receive either the drug or a placebo. The goal is to see if this approach lowers the number of first-time VAP cases within 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTILATOR ASSOCIATED PNEUMONIA (VAP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu Hospital of Shandong university
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.